SCHEMBL84033

SCHEMBL84033

COc1ccc(C(C)C)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.53
PPARD Q03181 1/20 0.53
PPARA Q07869 1/20 0.53
ACHE P22303 4/20 0.53
CA2 P00918 3/20 0.53
CA1 P00915 2/20 0.53
HDAC4 P56524 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CA12 O43570 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11951549 0.87 ALDH1A1 (0.54) PPARGPPARDPPARAACHECA2
SCHEMBL11951618 0.87 ALDH1A1 (0.47) PPARGPPARDPPARAACHECA2
SCHEMBL132840 0.86 HDAC4 (0.44) PPARGPPARDPPARAACHECA2
SCHEMBL130865 0.86 ACHE (0.46) PPARGPPARDPPARAACHECA2
SCHEMBL682781 0.84 GAA (0.56) PPARGPPARDPPARAKMT2AALDH1A1
SCHEMBL682779 0.84 ALDH1A1 (0.52) PPARGPPARDPPARAL3MBTL1ALDH1A1
SCHEMBL11951653 0.84 HDAC4 (0.43) PPARGPPARDPPARAACHECA2
SCHEMBL16386815 0.84 PDE4A (0.44) PPARGPPARDPPARAACHECA2
SCHEMBL12180453 0.84 PDE4B (0.44) PPARGPPARDPPARAACHECA2
SCHEMBL11951562 0.84 HDAC4 (0.43) PPARGPPARDPPARAACHECA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300030-A2 RICE BRAN EXTRACTS AND METHODS OF USE THEREOF Rice Science, Llc (US) 2011-03-30 EP claimed
US-20100015258-A1 Rice Bran Extracts and Methods of Use Thereof HALPERN, BARUCH 2010-01-21 US claimed
WO-2009143065-A2 RICE BRAN EXTRACTS AND METHODS OF USE THEREOF RICE SCIENCE, LLC (US) 2009-11-26 WO claimed
US-12043621-B2 Small molecule inhibitors of Interleukin-4 TRUSTEES OF BOSTON UNIVERSITY (US) 2024-07-23 US disclosed
US-12043621-B2 Small molecule inhibitors of Interleukin-4 TRUSTEES OF BOSTON UNIVERSITY (US) 2024-07-23 US disclosed
US-12030878-B2 Substituted indole ether compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-09 US disclosed
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PROMEGA CORPORATION 2024-02-29 US disclosed
US-11912703-B2 6-azaindole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-27 US disclosed
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same TREVENA, INC. (US) 2024-02-27 US disclosed
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF BLACKSMITH MEDICINES, INC. 2023-11-30 US disclosed
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF BLACKSMITH MEDICINES, INC. 2023-11-30 US disclosed
EP-0550111-A1 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them STERLING WINTHROP INC. (US) 1993-07-07 EP disclosed
EP-0550112-A1 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them STERLING WINTHROP INC. (US) 1993-07-07 EP disclosed
EP-0549073-A1 Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC. (US) 1993-06-30 EP disclosed
EP-0542372-A1 2-Substituted saccharin derivative proteolytic enzyme inhibitors STERLING WINTHROP INC. (US) 1993-05-19 EP disclosed
US-5187173-A Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders STERLING WINTHROP INC. (US) 1993-02-16 US disclosed
US-5128339-A Emphysema, rheumatoid arthritis, pancreatitis STERLING WINTHROP INC. (US) 1992-07-07 US disclosed
EP-0483928-A1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use STERLING WINTHROP INC. (US) 1992-05-06 EP disclosed
EP-0076220-B1 PROCESS FOR THE HYDROLYSIS OF ARYL ALIPHATIC ETHERS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1985-08-07 EP disclosed
EP-0076220-A1 Process for the hydrolysis of aryl aliphatic ethers RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1983-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382891-A1 GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF QPCT, QPCTL, GLUL PPARG 525/4885PPARD 1226/4885PPARA 910/4885
US-11912703-B2 6-azaindole compounds TLR7, TLR9, TLR5 PPARG 678/4885PPARD 2723/4885PPARA 2073/4885
US-12043621-B2 Small molecule inhibitors of Interleukin-4 IL4, IL2, IL4I1 PPARG 2408/4885PPARD 2236/4885PPARA 3101/4885
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same S1PR1, S1PR2, S1PR3 PPARG 1101/4885PPARD 725/4885PPARA 638/4885
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PGLS, AADAC, GLB1 PPARG 1540/4885PPARD 3040/4885PPARA 1994/4885
US-12030878-B2 Substituted indole ether compounds TLR7, TLR8, TLR1 PPARG 269/4885PPARD 1397/4885PPARA 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.